IngenOx has acquired global rights to zabinostat (CXD101) through an exclusive world-wide license agreement from AstraZeneca
SynOx Therapeutics (an IngenOx spin-out) has acquired global rights to emactuzumab through an exclusive world-wide license agreement from Roche
IngenOx has a sub-licensing and partnership agreement with Nuance Biotech to develop zabadinostat in China and South Africa
IngenOx has signed a memorandum of understanding (MOU) with Genor Biopharma relevant to the clinical development of zabadinostat
IngenOx has established a unique partnership with Oxford University Hospitals NHS Trust to facilitate its clinical trials and develop its precision medicine platform
SynOx Therapeutics is an IngenOx spin-out with a focus to deliver marketing approval for emactuzumab in diffuse tenosynovial giant cell tumour.
In December 2020, SynOx acquired a world-wide exclusive license for emactuzumab from Roche, and received €37 million investment from HealthCap, Medicxi, Forbion and Gimv.